IκB kinases increase Myc protein stability and enhance progression of breast cancer cells

Molecular Cancer

Volumn 10, Issue , 2011, Pages

  Yeh, Pei Yen ^a   Lu, Yen Shen ^a   Ou, Da Liang ^b   Cheng, Ann Lii ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BAY 110782; CYCLIN D1; DOXORUBICIN; I KAPPA B ALPHA; I KAPPA B BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MYC PROTEIN; TRANSCRIPTION FACTOR TWIST; UNCLASSIFIED DRUG; 3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; 3-(4-METHYLPHENYLSULFONYL)-2-PROPENENITRILE; I KAPPA B KINASE; NITRILE; SULFONE;

ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER INVASION; CARCINOGENESIS; CELL PROLIFERATION; CELL STRAIN MCF 7; GENETIC TRANSFECTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; SIGNAL TRANSDUCTION; BREAST TUMOR; CELL MOTION; CELL TRANSFORMATION; DISEASE COURSE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; FEMALE; GENETICS; METABOLISM; PHYSIOLOGY; PROTEIN BINDING; RNA STABILITY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; DOXORUBICIN; FEMALE; HUMANS; I-KAPPA B KINASE; NF-KAPPA B; NITRILES; PROTEIN BINDING; PROTEIN STABILITY; PROTO-ONCOGENE PROTEINS C-MYC; RNA STABILITY; RNA, MESSENGER; SIGNAL TRANSDUCTION; SULFONES;

EID: 79955882759     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-10-53     Document Type: Article

References (39)

1. Lee DF, Hung MC. Advances in targeting IKK and IKK-related kinases for cancer therapy. Clin Cancer Res 2008, 14:5656-5662. 10.1158/1078-0432.CCR-08-0123, 2613770, 18794072.
2. Cairo S, Wang Y, de Reyniès A, Duroure K, Dahan J, Redon MJ, Fabre M, McClelland M, Wang XW, Croce CM, Buendia MA. Stem cell-like micro-RNA signature driven by Myc in aggressive liver cancer. Proc Natl Acad Sci USA 2010, 107:20471-20476. 10.1073/pnas.1009009107, 21059911.
3. Israë A. The IKK complex, a central regulator of NF-κB activation. Cold Spring Harb Perspect Biol 2010, 2:a000158. 10.1101/cshperspect.a000158, 2829958, 20300203.
4. Perkins ND. Integrating cell-signalling pathways with NF-κB and IKK function. Nat Rev Mol Cell Biol 2007, 8:49-62. 10.1038/nrm2083, 17183360.
5. Hayden MS, Ghosh S. Shared principles in NF-κB signaling. Cell 2008, 132:344-362. 10.1016/j.cell.2008.01.020, 18267068.
6. Huber MA, Azoitei N, Baumann B, Grünert S, Sommer A, Pehamberger H, Kraut N, Beug H, Wirth T. NF-κB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest 2009, 114:569-581.
7. Idris AI, Libouban H, Nyangoga H, Landao-Bassonga E, Chappard D, Ralston SH. Pharmacologic inhibitors of IκB kinase suppress growth and migration of mammary carcinosarcoma cells in vitro and prevent osteolytic bone metastasis in vivo. Mol Cancer Ther 2009, 8:2339-2347.
8. Jiang R, Xia Y, Li J, Deng L, Zhao L, Shi J, Wang X, Sun B. High expression levels of IKKα and IKKβ are necessary for the malignant properties of liver cancer. Int J Cancer 2010, 126:1263-1274.
9. Kim HJ, Hawke N, Baldwin AS. NF-κB and IKK as therapeutic targets in cancer. Cell Death Differ 2006, 13:738-747. 10.1038/sj.cdd.4401877, 16485028.
10. Chariot A. The NF-κB-independent functions of IKK subunits in immunity and cancer. Trends Cell Biol 2010, 19:404-413.
11. Hu MC, Lee DF, Xia W, Golfman LS, Ou-Yang F, Yang JY, Zou Y, Bao S, Hanada N, Saso H, Kobayashi R, Hung MC. IκB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 2004, 117:225-237. 10.1016/S0092-8674(04)00302-2, 15084260.
12. Lamberti C, Lin KM, Yamamoto Y, Verma U, Verma IM, Byers S, Gaynor RB. Regulation of β-catenin function by the IκB kinases. J Biol Chem 2001, 276:42276-42286. 10.1074/jbc.M104227200, 11527961.
13. Carayol N, Wang CY. IKKα stabilizes cytosolic β-catenin by inhibiting both canonical and non-canonical degradation pathways. Cell Signal 2006, 18:1941-1946. 10.1016/j.cellsig.2006.02.014, 16616828.
14. Grandori C, Cowley SM, James LP, Eisenman RN. The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol 2000, 16:653-699. 10.1146/annurev.cellbio.16.1.653, 11031250.
15. David CJ, Chen M, Assanah M, Canoll P, Manley JL. HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 2010, 463:364-368. 10.1038/nature08697, 2950088, 20010808.
16. Gustafson WC, Weiss WA. Myc proteins as therapeutic targets. Oncogene 2010, 29:1249-1259. 10.1038/onc.2009.512, 2904682, 20101214.
17. Wolfer A, Wittner BS, Irimia D, Flavin RJ, Lupien M, Gunawardane RN, Meyer CA, Lightcap ES, Tamayo P, Mesirov JP, Liu XS, Shioda T, Toner M, Loda M, Brown M, Brugge JS, Ramaswamy S. MYC regulation of a "poor-prognosis" metastatic cancer cell state. Proc Natl Acad Sci USA 2010, 107:3698-3703. 10.1073/pnas.0914203107, 2840447, 20133671.
18. Trimboli AJ, Fukino K, de Bruin A, Wei G, Shen L, Tanner SM, Creasap N, Rosol TJ, Robinson ML, Eng C, Ostrowski MC, Leone G. Direct evidence for epithelial-mesenchymal transitions in breast cancer. Cancer Res 2008, 68:937-945. 10.1158/0008-5472.CAN-07-2148, 18245497.
19. Xu J, Chen Y, Olopade OI. MYC and Breast Cancer. Genes Cancer 2010, 1:629-640.
20. Eilers M, Eisenman RN. Myc's broad reach. Genes Dev 2008, 22:2755-2766. 10.1101/gad.1712408, 2751281, 18923074.
21. Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer 2008, 8:976-990. 10.1038/nrc2231, 19029958.
22. Adler AS, Lin M, Horlings H, Nuyten DSA, van de Vijver MJ, Chang HY. Genetic regulators of large-scale transcriptional signatures in cancer. Nat Genet 2006, 38:421-430. 10.1038/ng1752, 1435790, 16518402.
23. Podsypanina K, Du YC, Jechlinger M, Beverly LJ, Hambardzumyan D, Varmus H. Seeding and propagation of untransformed mouse mammary cells in the lung. Science 2008, 321:1841-1844. 10.1126/science.1161621, 2694414, 18755941.
24. Wierstra I, Alves J. The c-myc promoter: still mystery and challenge. Adv Cancer Res 2008, 99:113-333.
25. Levens D. You Don't Muck with MYC. Genes Cancer 2010, 1:547-554. 10.1177/1947601910377492, 2946075, 20882108.
26. Henriksson M, Bakardjiev A, Klein G, Lüscher B. Phosphorylation sites mapping in the N-terminal domain of c-myc modulate its transforming potential. Oncogene 1993, 8:3199-3209.
27. Lutterbach B, Hann SR. c-Myc transactivation domainassociated kinases: questionable role for map kinases in c-Myc phosphorylation. J Cell Biochem 1999, 72:483-491. 10.1002/(SICI)1097-4644(19990315)72:4<483::AID-JCB4>3.0.CO;2-I, 10022608.
28. Junttila MR, Puustinen P, Niemelä M, Ahola R, Arnold H, Böttzauw T, Ala-aho R, Nielsen C, Ivaska J, Taya Y, Lu SL, Lin S, Chan EK, Wang XJ, Grènman R, Kast J, Kallunki T, Sears R, Kähäri VM, Westermarck J. CIP2A Inhibits PP2A in Human Malignancies. Cell 2007, 130:51-62. 10.1016/j.cell.2007.04.044, 17632056.
29. Khanna A, Böckelman C, Hemmes A, Junttila MR, Wiksten JP, Lundin M, Junnila S, Murphy DJ, Evan GI, Haglund C, Westermarck J, Ristimäki A. MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J Natl Cancer Inst 2009, 101:793-805. 10.1093/jnci/djp103, 19470954.
30. Naidu R, Wahab NA, Yadav M, Kutty MK. Protein expression and molecular analysis of c-myc gene in primary breast carcinomas using immunohistochemistry and differential polymerase chain reaction. Int J Mol Med 2002, 9:189-196.
31. Pierce JW, Schoenleber R, Jesmok G, Best J, Moore SA, Collins T, Gerritsen ME. Novel inhibitors of cytokine-induced IκBα phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J Biol Chem 1997, 272:21096-21103. 10.1074/jbc.272.34.21096, 9261113.
32. Garcia M, Alaniz L, Lopes E, Blanco G, Hajos S, Alvarez E. Inhibition of NF-κB activity by BAY 11-7082 increases apoptosis in multidrug resistant leukemic T-cell lines. Leuk Res 2005, 29:1425-1434. 10.1016/j.leukres.2005.05.004, 15982733.
33. Puisieux A, Valsesia-Wittmann S, Ansieau S. A twist for survival and cancer progression. Brit J Cancer 2006, 94:13-17. 10.1038/sj.bjc.6602876, 2361066, 16306876.
34. Ansieau S, Morel AP, Hinkal G, Bastid J, Puisieux A. TWISTing an embryonic transcription factor into an oncoprotein. Oncogene 2010, 29:3173-3184. 10.1038/onc.2010.92, 20383196.
35. Otto T, Horn S, Brockmann M, Eilers U, Schüttrumpf L, Popov N, Kenney AM, Schulte JH, Beijersbergen R, Christiansen H, Berwanger B, Eilers M. Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell 2009, 15:67-78. 10.1016/j.ccr.2008.12.005, 19111882.
36. Soucek L, Whitfield J, Martins CP, Finch AJ, Murphy DJ, Sodir NM, Karnezis AN, Swigart LB, Nasi S, Evan GI. Modeling Myc inhibition as a cancer therapy. Nature 2008, 455:679-683. 10.1038/nature07260, 18716624.
37. Wong DJ, Liu H, Ridky TW, Cassarino D, Segal E, Chang HY. Module map of stem cell genes guides creation of epithelial cancer stem cells. Cell Stem Cell 2008, 2:333-344. 10.1016/j.stem.2008.02.009, 2628721, 18397753.
38. Kim J, Woo AJ, Chu J, Snow JW, Fujiwara Y, Kim CG, Cantor AB, Orkin SH. A Myc Network Accounts for Similarities between Embryonic Stem and Cancer Cell Transcription Programs. Cell 2010, 143:313-324. 10.1016/j.cell.2010.09.010, 3018841, 20946988.
39. Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NF-kB, Lin28, Let-7 microRNA, and IL6 links inflammation to cell transformation. Cell 2009, 139:693-706. 10.1016/j.cell.2009.10.014, 2783826, 19878981.